2018

PDF 1: FDA expedited report

PDF 2:  Drug shortages: update 

PDF 3:  Prescription drug donation 

2017

PDF 4:  Universal color scheme for respiratory inhalers 

PDF 5:  National drug shortages: update 

2016

PDF 6:  National drug shortages update 

PDF 7:  Hormone therapies: off-label uses and unapproved formulations 

2015

PDF 8:  National drug shortages update 

2014

PDF 9:  National drug shortages update 

PDF 10:  Biosimilar product approval and marketing (summary only) 

2013

PDF 11:  National drug shortages update 

PDF 12:  Pharmacy compounding 

PDF 13:  A contemporary view of national drug control policy 

2012

PDF 14:  Drug shortages update 

PDF 15:  National drug shortages update 

PDF 16:  Risk evaluation and mitigation strategies 

2011

PDF 17:  An abbreviated approval pathway for biosimilars 

PDF 18:  National drug shortages 

2010

PDF 19:  The evolving culture of drug safety in the united states: risk evaluation and mitigation strategies (REMS) 

2009

PDF 20:  Use of cannabis for medicinal purposes 

2008

PDF 21:  Improving medical practice and patient/family education to reverse the epidemic of nonmedical prescription drug use and addiction 

2007

PDF 22:  Generic substitution of narrow therapeutic index drugs 

PDF 23:  Standards, laws, and regulations addressing pain medications and medical practice

 

LINK 1: Access council reports prior to 2007.

LINK 2: Learn more about the Council on Science and Public Health.

2018

PDF 1: FDA expedited report

PDF 2:  Drug shortages: update 

PDF 3:  Prescription drug donation 

2017

PDF 4:  Universal color scheme for respiratory inhalers 

PDF 5:  National drug shortages: update 

2016

PDF 6:  National drug shortages update 

PDF 7:  Hormone therapies: off-label uses and unapproved formulations 

2015

PDF 8:  National drug shortages update 

2014

PDF 9:  National drug shortages update 

PDF 10:  Biosimilar product approval and marketing (summary only) 

2013

PDF 11:  National drug shortages update 

PDF 12:  Pharmacy compounding 

PDF 13:  A contemporary view of national drug control policy 

2012

PDF 14:  Drug shortages update 

PDF 15:  National drug shortages update 

PDF 16:  Risk evaluation and mitigation strategies 

2011

PDF 17:  An abbreviated approval pathway for biosimilars 

PDF 18:  National drug shortages 

2010

PDF 19:  The evolving culture of drug safety in the united states: risk evaluation and mitigation strategies (REMS) 

2009

PDF 20:  Use of cannabis for medicinal purposes 

2008

PDF 21:  Improving medical practice and patient/family education to reverse the epidemic of nonmedical prescription drug use and addiction 

2007

PDF 22:  Generic substitution of narrow therapeutic index drugs 

PDF 23:  Standards, laws, and regulations addressing pain medications and medical practice

 

LINK 1: Access council reports prior to 2007.

LINK 2: Learn more about the Council on Science and Public Health.

PDF 2: 2018

CSAPH-report 2-A-18

PDF 3: 2018

CSAPH-report 3-A-18

PDF 5: 2017

CSAPH-report 4-I-17

PDF 6: 2016

CSAPH report 2-I-16

PDF 8: 2015

CSAPH report 2-I-15

PDF 9: 2014

CSAPH report 3-A-14

PDF 11: 2013

CSAPH report 8-A-13

PDF 12: 2013

CSAPH report 9-A-13

PDF 15: 2012

CSAPH report 2-I-12

PDF 18: 2011

CSAPH report 2-I-11

Why Join the AMA?

An AMA membership means you are passionate about meaningful innovation to enable a better health care system for patients and physicians. You deserve a strong AMA.  Give membership a try.

Join